Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy-Reference-Cited by-同舟云学术

Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy

Published:2016-10-18 Issue:1 Volume:6 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Fujii Chihiro,Kondo Takayuki,Ochi Hirofumi,Okada Yoichiro,Hashi Yuichiro,Adachi Tetsuya,Shin-Ya Masaharu,Matsumoto Sadayuki,Takahashi Ryosuke,Nakagawa Masanori,Mizuno Toshiki

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep35314.pdf

Reference51 articles.

1. Sospedra, M. & Martin, R. Immunology of multiple sclerosis. Annual review of immunology 23, 683–747 (2005).

2. Axtell, R. C. et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nature medicine 16, 406–412 (2010).

3. Sallusto, F. et al. T-cell trafficking in the central nervous system. Immunological reviews 248, 216–227 (2012).

4. Steinman, L. Immunology of relapse and remission in multiple sclerosis. Annual review of immunology 32, 257–281 (2014).

5. Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature reviews. Drug discovery 9, 883–897 (2010).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis;Clinical and Experimental Immunology;2024-04-16

2. Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice;International Immunopharmacology;2023-12

3. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis;Expert Opinion on Pharmacotherapy;2023-03-04

4. Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination;Clinical & Translational Immunology;2023-01

5. Cytotoxic T lymphocytes in multiple sclerosis: New targets for treatment?;Translational Neuroimmunology, Volume 8;2023